Booking 50% and 103.70% Gains — and another Bet on Red Hot Pharma

Nicholas Vardy

Nicholas Vardy has a unique background that has proven his knack for making money in different markets around the world.

It was a mixed week in global stock markets last week with the Dow Jones down 0.20% and the S&P 500 rising 0.60%. The MCSI Emerging Markets Index ended the week 0.37% higher.

Your Bull Market Alert portfolio did much better, however, with the Bank of Ireland (IRE) soaring 21.64%; Apollo Global Management, LLC (APO) jumping 7.75%; the iShares MSCI Spain Capped Index (EWP) leaping 6.91%; and Trina Solar Limited (TSL) adding 5.93%.

With your Apollo Global Management, LLC (APO) March $32.50 call options up 50% in just five days, sell half of your options to lock in these big, quick gains.

You sold half of your Bank of Ireland (IRE) April $15 call options on Friday for a 66.67% gain. Sell your remaining options for another 103.70% gain.

This week’s Bull Market Alert recommendation, AbbVie Inc. (ABBV), takes you back into the red-hot pharmaceutical sector.

AbbVie was spun off from medical device maker Abbott Laboratories (ABT) a little over a year ago, on January 1, 2013. Since then, the stock has been on a tear, rising 49.71% over the past 12 months.

Despite this already substantial rise, here’s why I expect AbbVie (ABBV) to move still higher in the weeks ahead.

First, AbbVie sells a wide range of popular, branded prescription drugs, including the blockbuster anti-inflammatory drug Humira, used to treat rheumatoid arthritis, psoriasis and Crohn’s disease. Humira also happens to be the world’s best-selling prescription drug, with sales of $7.6 billion in just the first nine months of 2013.

In addition, Abbvie is also developing a wide range of treatments in the areas of neuroscience, oncology and autoimmune diseases. Several of Abbvie’s drugs are in the midst of the FDA approval. The company’s strong drug pipeline ensures that the company will be delivering a steady stream of consistent positive short- to medium-term news, which in turn should continue to support consistent share-price appreciation.

Exclusive  Seeking a Potential "Triple" by the End of 2011

Second, AbbVie boasts both strong fundamentals and an attractive valuation. In 2012, AbbVie generated a return on assets base of 19.5% — a very high figure. By way of comparison, GlaxoSmithKline (GSK) eked out return on assets of 11.4% and Johnson & Johnson (JNJ) a mere 8.7%. Yet, AbbVie trades on a forward price-to-earnings (P/E) ratio of 15.96, a discount to both the pharma sector and the broader S&P 500.

Third, AbbVie is currently technically oversold by all of my favorite measures like MACD and slow stochastics. It has likely bottomed over the short term and should bounce strongly over the next few weeks.

So buy AbbVie inc (ABBV) at market today, and place your initial stop at $45.00.

Analysts at Jeffries just raised their target price on the stock to $68.00. That’s 34.65% above Friday’s closing price of $50.50.

Note that you can expect Abbvie to drop today to the tune of 40 cents per share — the amount of its most recent dividend — as the stock goes ex-dividend.

If you want to play the options, I recommend the May $52.50 calls (ABBV140517C00052500).

Disclosure: Abbvie Inc. (ABBV) is the second-largest stock holding in my firm Global Guru Capital’s ”American Alpha” Investment Program, though it is held indirectly through exchange-traded funds.

Portfolio Update

Bank of Ireland (IRE) soared 21.64% last week as the stock rose to a new three-year high. IRE shares have doubled in value over just the last six months. The latest news highlighted IRE’s positive five-year bond issue last week, raising 750 million euros. IRE jumped back above the 50-day moving average (MA) and is now a BUY.

Exclusive  Bet on the ‘Google of Russia’

Google Inc. (GOOG) added 2.28% after hitting a new 52-week high earlier in the week. Deutsche Bank put GOOG on its “must own” list recently, keeping the stock as a “Buy” and targeting $1,220. Even CNBC’s Jim Cramer said on-air that he was a buyer. With the Google news commentary heating up, expect Google to run higher through its earnings announcement. GOOG will report earnings on Jan. 30, after markets close. GOOG is a BUY.

iShares MSCI Spain Capped Index (EWP) jumped 6.91% to hit a new 52-week high. Nearing the $40.00 mark, EWP is now comfortably above the $38.00 range it has struggled against since mid-October 2013. EWP appears well primed for future gains. EWP is a BUY.

Trina Solar Limited (TSL) added 5.93%. Jefferies initiated coverage on TSL last week, setting a “Buy” recommendation and a $23.10 price target — a whopping 42% above Friday’s close. TSL will mount an assault on the $18.00 price level over the coming weeks as it tries to push up past this significant resistance point and 52-week high. TSL is a BUY.

db X-trackers Harvest China ETF (ASHR) fell 2.99% last week. Chinese markets suffered overall last week on fears that a wave of new initial public offerings (IPOs) could hurt delicate market balances, pushing the Shanghai Composite index down 3% as well. However, some traders see Friday’s weaker-than-expected U.S. jobs report as a boost to Asian markets, as capital may begin looking for greener (and less overbought) pastures. ASHR is a BUY.

Apple Inc. (AAPL) dipped 1.49% over the last five trading days. Personal computer (PC) sales just closed out the worst year of declines ever. With Apple still leading as the world’s premier tablet maker, and tablets being the number one replacement device for the PC, Apple likely has a lucrative growth channel it can mine for many years to come. Apple will report earnings on Jan. 27, after markets close. AAPL dipped below the 50-day MA and is now a HOLD.

Exclusive  A Bet on Small Caps -- and a New Option in European Banking

Apollo Global Management, LLC (APO) jumped 7.75% for its first week in your portfolio to hit a new 52-week high. APO also managed to break a significant resistance level stretching back to October of 2013. APO may take a breather at the $35 price level but appears well positioned to move higher. APO is a BUY.

Be sure to sign up for my private, subscribers-only meeting if you plan to attend The World MoneyShow Orlando. The room for my private meeting is St. George 108, and my gathering is scheduled for Friday, Jan. 31, beginning at 1 p.m. I encourage you to sign up for my private meeting today. To attend The World MoneyShow Orlando, Jan. 31-Feb. 1, register today and attend free as my guest.

Latest Special Report

As a courtesy, I want to bring to your attention my latest special report, the newly updated version of The Top 12 Stocks You Should Buy Right Now, which features three of my top investment recommendations, as well as bonus picks from each of my fellow investment newsletter editors at Eagle.

Nicholas Vardy

Like This Article?
Now Get Our FREE Special Report:
Alternative Investing: Investing in Timber

Stock Investor editor Paul Dykewicz reveals why investing in timber may be one of the best long-term portfolio strategies you'll find today.

Get Access to the Report, 100% FREE


img
previous article

Questions or comments? What other investing topics would you like us to cover? Let us know in the box below...

 

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

LEARN MORE HERE

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

LEARN MORE HERE

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

LEARN MORE HERE

Mike Turner

Mike Turner’s financial, mathematical, computer science and engineering background serves as the foundation for his disciplined, rules-based approach to trading. Mike’s three services include:

Product Details

LEARN MORE HERE

Hilary Kramer

Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:

Product Details

LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

LEARN MORE HERE